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In the 1950s, the strategy of adding chloroquine to food salt as a prophylaxis against malaria was considered to be a 
successful tool. However, with the development of Plasmodium resistance in the Brazilian Amazon, this control strategy 
was abandoned. More than 50 years later, asexual stage resistance can be avoided by screening for antimalarial drugs 
that have a selective action against gametocytes, thus old prophylactic measures can be revisited. The efficacy of the 
old methods should be tested as complementary tools for the elimination of malaria.
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V gametocytes (Lobo & Kumar 1998, Baker 2010, 
Bousema & Drakeley 2011). Seven days after the onset 
of clinical symptoms, only mature stage V gametocytes 
can be identified in the peripheral blood circulation of 
an infected patient and these gametocytes can persist for 
weeks in the circulating blood (Smalley & Sinden 1977). 
Immature or early stage gametocytes (stages I to III) are 
often sensitive to shizonticidal drugs (Sinden & Smalley 
1979, Delves 2012, Delves et al. 2012) and circulating 
mature stage V gametocytes are sensitive to doses of 
primaquine (PQ) as low as 0.25 mg/kg (WHO 2012). On 
the contrary, Plasmodium vivax gametocytes are pres-
ent at the beginning of the infection, but only live in the 
blood for a few days (Bousema & Drakeley 2011). These 
biological differences between P. falciparum and P. 
vivax gametocytes suggest that the latter is more likely 
to maintain transmission to the vector before a proper 
diagnosis and treatment. Once chloroquine (CQ) or any 
other artemisinin-based combination therapy (ACT) is 
initiated, gametocytes (Douglas et al. 2012) and young 
trophozoites that are committed to gametocytogenesis 
are killed (Nosten 2010). Therefore, the discovery of P. 
vivax anti-gametocytocidal drugs has not been a priority 
in malaria control and elimination efforts. However, any 
therapeutic strategy that intends to kill P. vivax gameto-
cytes before treatment is initiated represents an innova-
tive method of controlling P. vivax transmission.
In 2000, the United Nations established the Millen-
nium Declaration, which aimed to halt and then reverse 
“the scourge of malaria” by 2015 (UN 2000). In 2007, 
the WHO published a manual with guidelines for malar-
ia elimination (WHO 2007), creating renewed attention 
and interest in the field. Since the manual’s publication, 
the major achievements and failures of the Italian Ma-
laria Eradication Campaign from the 1950s have been 
reconsidered. Many innovative strategies during the 
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Recent numbers from the World Health Organiza-
tion (WHO) demonstrate the importance of malaria in 
the global scenario. In the 2013 World Malaria Report, 
the number of malaria cases exceeded 200 million, with 
627,000 deaths (WHO 2013). These numbers have been 
fluctuating over recent decades, but in most endemic ar-
eas, no real possibility of elimination is expected in the 
next few years without envisioning new tools.
For reducing malaria transmission (i.e., malaria con-
trol), a successful programme should focus on several 
aspects, including early diagnosis, vector control and the 
use of effective antimalarial drugs. However, these strat-
egies need to be emphasised in the elimination scenario 
(Tauil 2011). Moreover, searching for each individual 
case of malaria is a priority in the context of achiev-
ing zero reported cases (malERA 2011). In this context, 
tools such as mass drug administration (MDA) and mass 
screening and treatment (MSAT) should be considered. 
However, other than unpublished experiences of indi-
vidual malaria control programmes, there is a lack of 
robust evidence supporting the efficacy of specific tools 
for malaria control and elimination.
Gametocyte stages are non-replicating forms that are 
responsible for the transmission of the malaria parasite 
to the mosquito vector. In contrast to other species of 
Plasmodium, Plasmodium falciparum gametocytes de-
velop through five morphologically distinct stages (I 
to V) and require 10-12 days to fully mature into stage 
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Italian campaign, including DDT spraying, focused on 
vector control (Majori 2012), but the addition of antima-
larials to daily consumed food received special attention. 
At the beginning of the 1950s, Mário Pinotti, a Brazilian 
pharmacist and physician, proposed the addition of CQ 
to food salt as a novel chemoprophylaxis against malaria 
(Pinotti 1953). While pyrimethamine was initially used, 
CQ was eventually selected because of pyrimethamine’s 
high toxicity. At that time, both P. falciparum and P. 
vivax were sensitive to CQ, which is safe for human con-
sumption (Coatney et al. 1958). On other continents, suc-
cessful trials using a weekly dose of CQ supported the 
proposed strategy (Clyde 1966, Giglioli et al. 1967, Hall 
& Wilks 1967, Motabar et al. 1971). During the same 
decade, similar experiments were successfully conduct-
ed in hospitals and in field conditions in Brazil (Pinotti 
1954, 1959, Pinotti et al. 1955a, b, Soares 1955, Pinotti 
& Soares 1956). A major problem with CQ-enriched salt 
was precipitation under conditions of high humidity and 
temperatures in the endemic areas, which left most of 
the active compound at the bottom of the packages. As a 
result of its strong bitterness, many people discarded the 
supplemented salt before a sufficient amount of the drug 
was consumed (PL Tauil, unpublished observations); in-
sufficient consumption of drugs is a known risk factor for 
the development of drug resistance. For this reason, after 
the first trial, Pinotti was concerned about the possibility 
of antimalarial resistance, which manifested years later 
in P. falciparum (da Silva & Hochman 2011). This result 
was crucial for abandoning this strategy. More recently, 
P. vivax has also developed resistance to CQ in the Ama-
zon (Alecrim et al. 1999, Santana Filho et al. 2007).
Currently, strategies such as MDA with low doses 
of PQ are a realistic tool for eliminating malaria in ar-
eas where P. falciparum is a major problem. However, 
even in areas where malaria control is effective, P. vivax 
becomes a major problem because of frequent relapses 
and insufficient attention to the potential gametocyte 
carriers. Therefore, the development of a drug that kills 
P. vivax gametocytes before the beginning of treatment 
could be a useful tool in controlling the transmission of 
this parasite. An innovative approach for malaria elimi-
nation would be the reintroduction of chemoprophylaxis 
by enriching food salt with a drug that is active exclusive-
ly against gametocytes, thereby avoiding the selection of 
resistant asexual stages against routinely used antima-
larials. For a chemoprophylactic strategy, the ideal drug 
should be (i) efficacious exclusively against gametocytes 
(to avoid cross-resistance with asexual stages), (ii) non-
toxic to humans at the recommended dosages, (iii) stable 
under environmental and cooking temperatures, (iv) ca-
pable of maintaining the original organoleptic charac-
teristics of the food and (v) safe in glucose-6-phosphate 
dehydrogenase (G6PD)-deficient populations.
PQ is currently available at low doses and tafeno-
quine, a new 8-aminoquinoline drug that is derived 
from PQ, and has a prolonged half-life, currently un-
dergoing Phase III trials as an antirelapse drug (Lla-
nos-Cuentas et al. 2013). These drugs are viable options 
for a chemoprophylactic strategy, however not safe for 
G6PD-deficient populations.
The identification of potential inhibitors of P. falci-
parum transmission has increased in recent years due to 
improvement in culture techniques. To catalyse the de-
velopment of new antimalarials, Medicines for Malaria 
Venture (MMV) and SCYNEXIS assembled the Malaria 
Box (Spangenberg et al. 2013), an open access library of 
400 compounds. The compounds were originally iden-
tified from phenotypic screening against P. falciparum 
asexual stages using over four million compounds from 
the research libraries of Saint Jude Children’s Research 
Hospital, Novartis and GlaxoSmithKline (Guiguemde et 
al. 2012). Laboratories around the world have taken the 
lead by testing these compounds against the late stages of 
P. falciparum gametocytes (Duffy & Avery 2013, Bow-
man et al. 2014, Sun et al. 2014). Compounds that appear 
to be specific against gametocytes have been identified 
and these compounds can potentially serve as starting 
points for the development of inhibitors that exclusively 
kill gametocytes. However, the selection of hit-to-lead 
compounds from multistage approaches is typically 
based on activity against both asexual and sexual stages, 
thereby providing less attention to agents that are only 
active against gametocytes. Although further investiga-
tion is required to discover more suitable leads for the 
proposed chemoprophylactic strategy, the concept itself 
may reopen an avenue to aid malaria elimination ef-
forts. These efforts may also include drugs that have a 
newly recognised action against malaria vectors, such 
as ivermectin, the safety of which was confirmed by the 
administration of millions of doses in MDA efforts for 
other neglected diseases (Chaccour et al. 2013).
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